If you have been reading about hGH fragment and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
== Mechanism == At the cellular level, metabolic myopathies lack some kind of enzyme or transport protein that prevents the chemical reactions necessary to create adenosine triphosphate (ATP). ATP is often referred to as the "molecular unit of currency" of intracellular energy transfer. The lack of ATP prevents the muscle cells from being able to function properly. Some people with a metabolic myopathy never develop symptoms due to the body's ability to produce enough ATP through alternative pathways (e.g. the majority of those with AMP-deaminase deficiency are asymptomatic). H2O + ATP → H+ + ADP + Pi + energy → muscle contraction ATP is needed for muscle contraction by two processes:
On March 10, 2023, Silicon Valley Bank (SVB) failed after a bank run, marking the third-largest bank failure in United States history and the largest since the 2008 financial crisis. It was one of three bank failures, along with Silvergate Bank and Signature Bank, in March 2023 in the United States. Seeking higher investment returns from its burgeoning deposits, SVB had dramatically increased its holdings of long-term securities since 2021, accounting for them on a hold-to-maturity basis. The market value of these bonds decreased significantly through 2022 and into 2023 as the Federal Reserve raised interest rates to curb an inflation surge, causing unrealized losses on the portfolio. Higher interest rates also raised borrowing costs throughout the economy and some Silicon Valley Bank clients started pulling money out to meet their liquidity needs. To raise cash to pay withdrawals by its depositors, SVB announced on Wednesday, March 8 that it had sold over US$21 billion worth of securities, borrowed $15 billion, and would hold an emergency sale of some of its treasury stock to raise $2.25 billion. The announcement, coupled with warnings from prominent Silicon Valley investors, caused a bank run as customers withdrew funds totaling $42 billion by the following day. On the morning of March 10, the California Department of Financial Protection and Innovation seized SVB and placed it under the receivership of the Federal Deposit Insurance Corporation (FDIC). An additional $100 billion were expected to be withdrawn during Friday.
Direct or tubed flaps involve having the flap connected to both the donor and recipient sites simultaneously, forming a bridge. This allows blood to be supplied by the donor site while a new blood supply from the recipient site is formed. Once this happens, the bridge can be disconnected from the donor site if necessary, completing the transfer. A free flap has the blood supply cut and then reattached microsurgically to a new blood supply at the recipient site.
Sources: en.wikipedia.org
It is possible that it may be related to Cirroteuthis, and in that case the two posterior stumps, looking like arms, may be the remains of the lateral fins, for they seem too far back for the arms, unless pulled out of position. On the other hand, they seem to be too far forward for fins. So that they are probably arms twisted out of their true position. However, having examined samples of the mass sent to him by Webb, Verrill concluded that "the creature cannot be an Octopus, but is of cetacean nature." He suggested that "the whole mass represents the upper part of the head of [a sperm whale], detached from the skull and jaw." Webb decided the carcass should be moved further inland so that it would not be lost to the sea forever. With the help of "six horses and strong tackle", it was moved several miles closer to St. Augustine, "to the terminus of a railroad," where it was protected from the tide and drifting sand. Its final resting place was South Beach, Anastasia Island, near the hotel of Dr. George Grant. The St. Augustine carcass became somewhat of a tourist attraction and was visited by large numbers of people. It is unknown what happened to the carcass afterwards. Photographs of the St. Augustine carcass were for a long time thought to be lost, and drawings remained the only pictorial evidence of the event. They were finally rediscovered in 1993 by Marjorie Blakoner of California, who recognised them in an old album. Van Lockwood, one of the original photographers of the St. Augustine carcass, kept an album of photos he had taken between 1885 and 1899.
A new French commander in chief and high commissioner, General Jean Marie de Lattre de Tassigny, was appointed in December 1950. With him began the construction of a defensive line of fortifications around the Red River Delta, to protect against Việt Minh incursions and against a possible Chinese invasion. It became known as the De Lattre Line. In 1950 and 1951, de Lattre implemented scorched earth tactics in an effort to limit Việt Minh access to food and other supplies. French forces burned crops in areas of Việt Minh activity. These tactics increased the anger of the Vietnamese people against the French and were a strategic failure. In late 1950 Giáp decided to go on a "general counteroffensive", seeking the final defeat of the French. On January 13, 1951, he moved the 308th and 312th Divisions, with more than 20,000 men, to attack Vĩnh Yên, 30 miles (48 km) northwest of Hanoi, which was manned by 6,000 French troops. Considered the first set-piece battle of the war, the Vietnamese saw initial success, although as the battle progressed, French aerial supremacy proved decisive as reinforcements flew in from the rest of Indochina and all available aircraft capable of dropping bombs was utilized to carry out what would be the largest aerial bombardment of the war. By noon of January 17, Giáp's troops withdrew in defeat. The Vietnamese had suffered 5,000–6,000 deaths and 500 combatants were captured. Giáp tried again to break the French defensive line, this time 20 miles (32 km) north-east of Haiphong in an attempt to cut the French access to the port city.
Other benefits to those of moderate mental health or moderate levels of flourishing were: stronger psychological and social performance, high resiliency, greater cardiovascular health, and an overall healthier lifestyle (Keyes, 2007). The encountered benefits of flourishing suggest a definition: "[flourishing] people experience high levels of emotional, psychological and social well being due to vigor and vitality, self-determination, continuous self- growth, close relationships and a meaningful and purposeful life" (Siang-Yang, 2006, p. 70).
[C(O)NH]3 ⇌ [C(O)NH]2[C(O)N]− + H+ (pKa = 6.88) [C(O)NH]2[C(O)N]− ⇌ [C(O)NH][C(O)N]22− + H+ (pKa = 11.40) [C(O)NH][C(O)N]22− ⇌ [C(O)N]33− + H+ (pKa = 13.5) Cyanuric acid is noted for its strong interaction with melamine, forming insoluble melamine cyanurate. This interaction locks the cyanuric acid into the tri-keto tautomer. Melamine cyanurate is cited as an example of supramolecular chemistry.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.